Neo Ivy Capital Management Acquires 97,042 Shares of Avantor, Inc. $AVTR

Neo Ivy Capital Management lifted its holdings in Avantor, Inc. (NYSE:AVTR) by 69.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 237,414 shares of the company’s stock after acquiring an additional 97,042 shares during the period. Neo Ivy Capital Management’s holdings in Avantor were worth $2,963,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its stake in Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after acquiring an additional 1,189 shares during the last quarter. Strategic Wealth Investment Group LLC bought a new stake in shares of Avantor in the 2nd quarter valued at approximately $32,000. Osaic Holdings Inc. lifted its stake in shares of Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock valued at $38,000 after purchasing an additional 1,064 shares during the last quarter. Spire Wealth Management purchased a new position in shares of Avantor in the 2nd quarter worth approximately $47,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Avantor by 172.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,709 shares of the company’s stock worth $46,000 after purchasing an additional 2,346 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Insider Transactions at Avantor

In other news, Director Gregory L. Summe purchased 100,000 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $9.40 per share, for a total transaction of $940,000.00. Following the completion of the acquisition, the director owned 400,000 shares of the company’s stock, valued at approximately $3,760,000. This trade represents a 33.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gregory T. Lucier acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was purchased at an average cost of $9.16 per share, for a total transaction of $458,000.00. Following the purchase, the director owned 50,000 shares of the company’s stock, valued at $458,000. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

AVTR has been the topic of several recent research reports. UBS Group restated a “neutral” rating and set a $10.50 price target on shares of Avantor in a report on Thursday, February 12th. Stifel Nicolaus set a $10.00 price objective on shares of Avantor in a research note on Thursday, February 12th. TD Cowen reiterated a “hold” rating on shares of Avantor in a research report on Thursday, February 12th. Barclays reissued an “underweight” rating and issued a $8.50 target price on shares of Avantor in a research note on Friday. Finally, Wells Fargo & Company lowered their target price on shares of Avantor from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Avantor has a consensus rating of “Hold” and an average price target of $11.80.

Avantor News Roundup

Here are the key news stories impacting Avantor this week:

• Neutral Sentiment: Barclays reaffirmed an “underweight” rating and set a $8.50 price target (small upside relative to the current price), signaling limited near-term upside and continued cautious analyst positioning. Barclays Reaffirmation
• Neutral Sentiment: A recent Yahoo Finance piece outlines how analysts are resetting fair-value targets for Avantor, documenting the shift in analyst views but not pointing to an immediate positive catalyst. How The Avantor Story Is Shifting
• Negative Sentiment: Unusually large put-option volume: investors bought ~94,708 puts (up ~1,582% vs. typical), indicating significant bearish positioning or hedging activity that can amplify downside volatility.
• Negative Sentiment: Zacks Research issued a wave of cuts to quarterly and full-year EPS estimates, downgraded multiple forward-quarter forecasts and assigned AVTR a “Strong Sell” / Zacks Rank #5 — a material negative read on near-term fundamentals and sentiment. Zacks Adds AVTR to Strong Sell List

Avantor Price Performance

Shares of AVTR stock opened at $8.18 on Friday. The stock has a 50 day moving average price of $10.70 and a 200 day moving average price of $11.86. Avantor, Inc. has a 52-week low of $8.14 and a 52-week high of $18.02. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.18 and a current ratio of 1.78. The firm has a market capitalization of $5.58 billion, a P/E ratio of -10.49, a P/E/G ratio of 3.34 and a beta of 0.97.

Avantor (NYSE:AVTR) last released its earnings results on Wednesday, February 11th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.01. The business had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. Avantor had a positive return on equity of 10.45% and a negative net margin of 8.09%.The business’s revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.27 earnings per share. Avantor has set its FY 2026 guidance at 0.770-0.830 EPS. As a group, sell-side analysts predict that Avantor, Inc. will post 1.06 earnings per share for the current year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.